Noramco, headquartered in Wilmington, Delaware, is a global leader in the production of controlled substances for the pharmaceutical industry, for medicines used to treat attention deficit hyperactivity disorder, pain, addiction, and for abuse-deterrent formulations. We realize our success through a keen focus on commercial and operational excellence as well as continuing strategic growth. Our global footprint includes Athens, GA, Wilmington, DE and Neuhausen, Switzerland. Specialists in controlled substance development and manufacturing, Noramco is a partner to the pharmaceutical industry: – Focusing on high-purity controlled substances – Leveraging intellectual property to devise the most efficient routes to APIs – Providing analytical data, chemical and physical properties, stability studies and regulatory assistance – Formulation friendly particle size grades and extended technical packages – Delivering DEA-compliant security and production capacity, from kilos to multi-ton supply – Supporting world-class supply security of controlled-substances, from schedule I to schedule III
Looking for a particular Noramco™ employee's phone or email?
The Noramco™ annual revenue was $57.8 million in 2026.
Scott Warner is the Vice President Government Relations and General Counsel of Noramco™.
109 people are employed at Noramco™.
Noramco™ is based in Wilmington, Delaware.
The NAICS codes for Noramco™ are [325, 32541, 3254, 32].
The SIC codes for Noramco™ are [283, 28].